Please assess the completion status of the following clinical trial:

Trial Title: Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed and dated by study patient and investigator/authorized physician~* Minimum age of 18 years~* Ability to understand the nature and requirements of the study~* ESKD patients on maintenance hemodialysis with a minimum of 4hrs three times a week at the time of recruitment and a dialysis vintage ≥3 months in NC clinics~* Patients that already received three doses against COVID-19 as detailed in the manufacturer's instructions~* Patients that are scheduled to receive a fourth vaccine dose of either Comirnaty (BioNTech/Pfizer) or Spikevax (Moderna) after approval of respective national authority.~Exclusion Criteria:~* Any conditions which could interfere with the patient's ability to comply with the study~* Participation in an interventional clinical study during the preceding 30 days~* Previous participation in the same study~* Patients with proven current COVID-19 infection as identified by routine clinical practice~* Patient in therapy with immunosuppressive medications / immunomodulators~* Patients who already received a fourth COVID-19 vaccination dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).